Financial Performance - The company's revenue for Q1 2023 was RMB 189,387,628.40, representing a year-on-year increase of 58.99%[5] - Pharmaceutical sales revenue reached RMB 151,370,102.78, an increase of 43.46% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of RMB 12,406,466.71, with no applicable year-on-year comparison[5] - Total operating revenue for Q1 2023 was RMB 189,387,628.40, an increase of 59% compared to RMB 119,120,479.12 in Q1 2022[21] - The net loss attributable to shareholders of the parent company was RMB -12,406,466.71, compared to a loss of RMB -118,242,516.18 in the same period last year, indicating a significant improvement[22] - The comprehensive loss for the period was RMB -100,502,461.88, compared to RMB -141,110,240.31 in the previous year, showing an improvement of approximately 29%[23] - Basic earnings per share for Q1 2023 was -0.01, compared to -0.08 in Q1 2022, indicating a reduction in loss per share[23] Cash Flow and Liquidity - The net cash flow from operating activities was negative at RMB -153,933,775.03[5] - In Q1 2023, the total cash inflow from operating activities was CNY 187,540,094.29, an increase from CNY 139,499,711.45 in Q1 2022, representing a growth of approximately 34.4%[25] - The net cash flow from operating activities was negative at CNY -153,933,775.03, compared to CNY -137,986,042.27 in the same period last year, indicating a decline in operational cash generation[25] - The total cash and cash equivalents at the end of Q1 2023 were CNY 3,993,788,388.71, down from CNY 1,466,666,021.40 at the end of Q1 2022, reflecting a decrease of approximately 72.8%[26] - The company reported a total cash outflow of CNY 186,195,342.28 in Q1 2023, compared to a much larger outflow of CNY 1,770,818,284.18 in Q1 2022, indicating a significant improvement in cash management[26] Research and Development - R&D expenses totaled RMB 140,950,687.03, accounting for 74.42% of revenue, a decrease of 34.20 percentage points year-on-year[6] - Research and development expenses increased to RMB 140,950,687.03, up from RMB 129,396,070.62, reflecting a growth of about 8.5%[21] Assets and Liabilities - The total assets at the end of the reporting period were RMB 10,215,914,005.30, a decrease of 1.09% from the end of the previous year[6] - The total assets as of March 31, 2023, amounted to CNY 10,215,914,005.30, a decrease from CNY 10,328,783,979.11 at the end of 2022[17] - The total liabilities decreased to RMB 2,647,592,989.19 from RMB 2,684,457,313.64, a reduction of approximately 1.4%[22] - The total equity attributable to shareholders of the parent company was RMB 7,522,918,266.25, down from RMB 7,597,101,016.92, a decrease of about 1%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,135[10] - The top ten shareholders hold a combined 41.13% of shares, with HKSCC NOMINEES LIMITED holding the largest share at 725,666,837 shares[12] - Vivo Capital Fund VIII, L.P. and its concerted actions hold 129,668,118 shares, representing 7.35%[14] Foreign Exchange and Financial Expenses - The company experienced a negative impact of CNY -21,312,065.11 from foreign exchange fluctuations on cash and cash equivalents[26] - The company reported a financial expense of RMB -101,409,201.80, which is a significant increase from RMB -37,723,802.06 in the previous year[21] Inventory and Receivables - Accounts receivable increased to CNY 131,389,817.39 from CNY 127,824,970.72[17] - Inventory rose significantly to CNY 98,915,173.76 compared to CNY 65,321,825.92[18] Investment Activities - The cash inflow from investment activities totaled CNY 41,307,536.32, down from CNY 55,785,270.27 in Q1 2022, a decrease of approximately 26.0%[25] - The net cash flow from investment activities was negative at CNY -1,915,385.25, compared to CNY -1,613,305,227.02 in the previous year, indicating a significant reduction in investment losses[25] - Cash outflows for the acquisition of fixed assets and intangible assets were CNY 43,222,921.57, significantly lower than CNY 204,862,322.68 in Q1 2022, showing a decrease of about 78.9%[25] Collaboration and Rights - The company regained global rights for the drug Oubatinib after terminating a collaboration agreement with BeiGene, which included a one-time payment of USD 125 million[16]
诺诚健华(09969) - 2023 Q1 - 季度业绩